These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 26456305

  • 1. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).
    Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, Wallach J, Halberstadt AL.
    Drug Test Anal; 2016 Sep; 8(9):891-902. PubMed ID: 26456305
    [Abstract] [Full Text] [Related]

  • 2. Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ).
    Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, Burrow TE, Chapman SJ, Stratford A, Nichols DE, Halberstadt AL.
    Drug Test Anal; 2017 Jan; 9(1):38-50. PubMed ID: 27265891
    [Abstract] [Full Text] [Related]

  • 3. Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).
    Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, Wallach J, Halberstadt AL.
    Drug Test Anal; 2019 Aug; 11(8):1122-1133. PubMed ID: 31083768
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
    Halberstadt AL, Chatha M, Klein AK, McCorvy JD, Meyer MR, Wagmann L, Stratford A, Brandt SD.
    Neuropharmacology; 2020 Aug 01; 172():107856. PubMed ID: 31756337
    [Abstract] [Full Text] [Related]

  • 5. Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).
    Brandt SD, Kavanagh PV, Westphal F, Stratford A, Odland AU, Klein AK, Dowling G, Dempster NM, Wallach J, Passie T, Halberstadt AL.
    Drug Test Anal; 2020 Jun 01; 12(6):812-826. PubMed ID: 32180350
    [Abstract] [Full Text] [Related]

  • 6. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).
    Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL.
    Drug Test Anal; 2018 Feb 01; 10(2):310-322. PubMed ID: 28585392
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).
    Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, Nichols DE, Brandt SD.
    Psychopharmacology (Berl); 2019 Feb 01; 236(2):799-808. PubMed ID: 30298278
    [Abstract] [Full Text] [Related]

  • 8. Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD).
    Brandt SD, Kavanagh PV, Westphal F, Pulver B, Morton K, Stratford A, Dowling G, Halberstadt AL.
    Drug Test Anal; 2022 Apr 01; 14(4):733-740. PubMed ID: 34837347
    [Abstract] [Full Text] [Related]

  • 9. Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD.
    Brandt SD, Kavanagh PV, Westphal F, Pulver B, Schwelm HM, Whitelock K, Stratford A, Auwärter V, Halberstadt AL.
    Drug Test Anal; 2022 Aug 01; 14(8):1503-1518. PubMed ID: 35524430
    [Abstract] [Full Text] [Related]

  • 10. Return of the lysergamides. Part III: Analytical characterization of N6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD).
    Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, Nichols DE, Halberstadt AL.
    Drug Test Anal; 2017 Oct 01; 9(10):1641-1649. PubMed ID: 28342178
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement.
    Halberstadt AL, Geyer MA.
    Psychopharmacology (Berl); 2013 Jun 01; 227(4):727-39. PubMed ID: 23407781
    [Abstract] [Full Text] [Related]

  • 12. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.
    Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD.
    Neuropharmacology; 2020 May 01; 167():107933. PubMed ID: 31917152
    [Abstract] [Full Text] [Related]

  • 13. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex.
    Gresch PJ, Smith RL, Barrett RJ, Sanders-Bush E.
    Neuropsychopharmacology; 2005 Sep 01; 30(9):1693-702. PubMed ID: 15756304
    [Abstract] [Full Text] [Related]

  • 14. Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice.
    de la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, González-Maeso J.
    ACS Chem Neurosci; 2022 Aug 17; 13(16):2436-2448. PubMed ID: 35900876
    [Abstract] [Full Text] [Related]

  • 15. Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex.
    Schindler EA, Harvey JA, Aloyo VJ.
    Brain Res; 2013 Jan 23; 1491():98-108. PubMed ID: 23123701
    [Abstract] [Full Text] [Related]

  • 16. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
    Rickli A, Moning OD, Hoener MC, Liechti ME.
    Eur Neuropsychopharmacol; 2016 Aug 23; 26(8):1327-37. PubMed ID: 27216487
    [Abstract] [Full Text] [Related]

  • 17. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD).
    Schindler EA, Dave KD, Smolock EM, Aloyo VJ, Harvey JA.
    Pharmacol Biochem Behav; 2012 Mar 23; 101(1):69-76. PubMed ID: 22197710
    [Abstract] [Full Text] [Related]

  • 18. Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats.
    Popik P, Krawczyk M, Kuziak A, Bugno R, Hogendorf A, Staroń J, Nikiforuk A.
    J Psychopharmacol; 2019 Nov 23; 33(11):1447-1455. PubMed ID: 31452444
    [Abstract] [Full Text] [Related]

  • 19. Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways.
    López-Giménez JF, González-Maeso J.
    Curr Top Behav Neurosci; 2018 Nov 23; 36():45-73. PubMed ID: 28677096
    [Abstract] [Full Text] [Related]

  • 20. Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites.
    Buchborn T, Schröder H, Dieterich DC, Grecksch G, Höllt V.
    Behav Brain Res; 2015 Mar 15; 281():62-8. PubMed ID: 25513973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.